Oh oh, Ad Blocker gedecteerd!
Het lijkt erop dat je een Ad Blocker gebruikt op De Beleggersgids. Gelieve de Ad Blocker uit te schakelen en advertenties toe te laten op onze website. De Beleggersgids is afhankelijk van inkomsten uit advertenties om jou alle artikels gratis te brengen. Gun je ons geen inkomsten? Ga verder

UCB (Euronext Brussels: UCB) and Amgen (NASDAQ:AMGN) today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for romosozumab, an investigational, monoclonal antibody for the treatment of osteoporosis in postmenopausal women at increased risk of fracture. Romosozumab works by binding and inhibiting sclerostin, a protein naturally occurring in the bone, thereby increasing bone formation and decreasing bone resorption.

“Osteoporosis is a chronic disease, largely asymptomatic, and often undetected until a fragility fracture occurs.1,2,3 Many patients view fragility fractures as part of aging4 but these fractures are an indication of a weakened skeleton and a signal for intervention with medication,” said Dr Pascale Richetta, Head of Bone and Executive Vice President at UCB. “We are pleased to submit the first regulatory submission for romosozumab, and are committed to seeking global regulatory approvals in the hopes of making this important therapy available for appropriate patients at increased risk of fracture.”

 

The BLA for romosozumab is based on data from the pivotal Phase 3 placebo-controlled FRActure study in post-menopausal woMen with ostEoporosis (FRAME) in approximately 7,200 patients. UCB and Amgen plan to present results from the FRAME clinical trial at an upcoming medical congress.

“Osteoporosis is a large public health problem yet is often overlooked, even in patients who have already experienced an osteoporotic fracture,”1,5said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen. “This BLA submission is an exciting milestone; romosozumab has the potential to reduce the risk of fractures and help patients suffering from this serious disease.”

Osteoporosis-related fragility fractures are common.,1,6 In the United States, one in two women over the age of 50 will experience an osteoporotic fracture.7 Data shows that only about 20 percent of women who have experienced a fracture receive any type of osteoporosis treatment during the first year post fracture.1

References

  1. Reginster JY, Burlet N. Osteoporosis: A still increasing prevalence. Bone. 2006 Feb;38 (2 Suppl 1):S4-9.
  2. International Osteoporosis Foundation. The Global Burden of Osteoporosis. What you need to know. Available at:  http://www.iofbonehealth.org/data-publications/fact-sheets/what-you-need-know-about-osteoporosis. Accessed July 14, 2016.
  3. International Osteoporosis Foundation. Who’s at Risk? 2015. Available at: http://www.iofbonehealth.org/whosrisk. Accessed July 15, 2016.
  4. National Osteoporosis Foundation. What Women Need To Know. Available at: www.nof.org/prevention/general-facts/what-women-need-to-know. Accessed July 15, 2016.
  5. Wilk A et al. Post-fracture pharmacotherapy for women with osteoporotic fracture: analysis of a managed care population in the USA. Osteoporosis Int. 2014;25(12):2777-2786.
  6. American Academy of Orthopaedic Surgeons. Position Statement: Osteoporosis/Bone Health in Adults as a National Public Health Priority. December 2014. Available at: www.aaos.org/about/papers/position/1113.asp Accessed July 14, 2016.
  7. National Osteoporosis Foundation. What Is Osteoporosis and What Causes It? Available at: https://www.nof.org/patients/what-is-osteoporosis. Accessed July 15, 2016.
306 lezers bereikt
De Beleggersgids Redactie

1. Like onze Facebook pagina
2. Volg ons op Twitter
3. Schrijf je in op onze nieuwsbrieven
4. Plaats een berichtje op ons forum

De Beleggersgids

Heldere en begrijpbare kennis, inzichten, inspiratie en nieuws over investeren in vastgoed, beleggingen, investeringen en geld.

Al 7.627 abonnees en groeiend

Top
×

De interessantste artikels wekelijks in je mailbox? Schrijf je in!

Ik ga akkoord met de voorwaarden
×

De interessantste artikels in je mailbox.

Ik ga akkoord met de voorwaarden